The therapeutic importance of such compounds has been demonstrated by the progression of HDAC/kinase dual inhibitors into clinical trials for cancer treatment (Figure 3b)—CUDC-101 (HDAC/EGFR inhibitor) and CUDC-907 (HDAC/PI3K inhibitor) [60,61,62,63,64]. The gene discussed is EGFR; the disease is cancer.